Volver a la clasificación

Thermo Fisher Scientific Inc (TMO)

Sobrevalorada
HealthcareDiagnostics & ResearchUnited States

Fundamental

61

Precio

$675.05

Capitalización Bursátil

$250.91B

Parte 1 · Cuánto vale la empresa

Resumen

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance y Liquidez

Ingresos

$46.34B

Últimos 12 meses (hasta 27/6/2026)

Beneficio Neto

$6.97B

Últimos 12 meses (hasta 27/6/2026)

Flujo de Caja Libre

$6.29B

Patrimonio Neto Total

$53.41B

Pasivo Total

$56.93B

Ratio de Liquidez

1.55

Cobertura de Intereses

5.46

Deuda/EBITDA

3.62

Beneficio Por Acción

Ingresos y Beneficio Neto

Flujo de Caja Libre

Desglose de Ingresos

Estado histórico

Márgenes en el tiempo

La deuda en el tiempo

Cuánto pesa la deuda

Cuadro de crecimiento

Crecimiento — Ingresos

Estimación de Valor Justo

Caso generalSobrevalorado

Valor Justo

$437.42

Precio Actual

$675.05

Margen de Seguridad

-54.3%

Rango de Valor Justo

$284.32 - $590.52

Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.

Métodos de Estimación

Precio objetivo de los analistas:$653.11
Flujo de caja descontado (DCF):$291.26
Múltiplo sobre beneficios (P/E):$455.96
Fórmula de crecimiento de Graham:$207.75
Valor de la capacidad de generar beneficios (EPV):$187.20
P/B justificado:$251.52
Descuento de dividendos (Gordon):$33.18
P/FFO, fondos de operaciones:Datos insuficientes para calcularlo
Beneficios de mitad de ciclo:$349.15
Múltiplo sobre ingresos:$492.07
Consenso de Analistas:Compra Fuerte (29B / 7H / 0S)
Última Sorpresa de Resultados:+4.54%

Métricas de Valoración

Ratio P/E

36.31

ROE

12.6%

Ratio P/B

4.74

P/FCF

34.11

Margen Bruto

-

ROIC

6.6%

Radar de Rentabilidad

Creación de Valor (Ventaja Competitiva)

ROIC

6.6%

WACC

8.3%

ROIC − WACC

-1.7 pp

El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.

Criterios de Análisis Fundamental

Superado (19)

  • EPS shows upward trend
  • EPS CAGR 13.95%
  • Price CAGR 15.76%
  • ROIC 6.6%
  • Debt/Equity ratio
  • Operating Margin 17.6%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 13.3%
  • Revenue Growth 5Y 6.7%
  • Analyst Consensus 81% Buy
  • Earnings Surprise avg 3.2%
  • Earnings Quality (OCF/NI) 1.29
  • Share Dilution -1.4%
  • Piotroski F-Score 5/9

Fallido (7)

  • P/FCF 34.11
  • P/B Ratio 4.74
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 16.99
  • Net Margin Trend 15.0% vs 15.2%

No disponible (2)

  • Gross Margin NaN%
  • Dividend Payout NaN%

Piotroski F-Score

5/9

Señales mixtas: algunas áreas requieren atención

score
criteria

Calidad de los Beneficios

1.29

Alta calidad: beneficios respaldados por efectivo

Dilución de Acciones

-1.4%

Recomprando acciones. Favorable para el accionista

Participaciones institucionales

Gobernanza

Equipo Directivo

NombreCargoEdad
Mr. Marc N. CasperChairman & CEO57
Mr. Gianluca PettitiPresident, COO & President of Products and Technologies46
Mr. James R. MeyerSenior VP & CFO45
Mr. Joseph R. HolmesVP & Chief Accounting Officer45
Mr. Ryan J. SnyderSenior VP & Chief Information Officer-
Dr. Karen E. Nelson Ph.D.Chief Scientific Officer-
Mr. Rafael TejadaVice President of Investor Relations-
Mr. Thomas Bailey Shropshire Jr.Senior VP and General Counsel-
Ms. Sandy B. PoundVP & Chief Communications Officer-
Mr. Alan J. MalusSenior Vice President of Strategy & Corporate Development65

Riesgo de Auditoría

2

Riesgo del Consejo

7

Riesgo de Compensación

10

Riesgo de Derechos del Accionista

1

Parte 2 · El precio y el momento de entrar

Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.

Documentos

  • Informe anual (10-K)

    Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.

    Presentado el 2026-02-26

    Ver documento
  • Informe trimestral (10-Q)

    Una actualización del desempeño financiero de los últimos tres meses.

    Presentado el 2026-07-31

    Ver documento
  • Informe de hecho relevante (8-K)

    Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.

    Presentado el 2026-07-23

    Ver documento

via SEC EDGAR

Historial de Resultados

via SEC EDGAR

Latest News

Recent headlines for TMO, sourced from Markets Gazette.

  • 5/25/2026POSITIVE
    If You Invested $1000 In Thermo Fisher Scientific Stock 20 Years Ago, You Would Have This Much Today

    An investment of $1000 in Thermo Fisher Scientific (TMO) stock 20 years ago would have yielded a substantial return, illustrating the company's long-term growth trajectory. While the exact final value is not provided in this snippet, historical performance data suggests significant capital appreciation. This underscores Thermo Fisher's consistent operational success and market leadership in the life sciences and diagnostics sectors. Investors considering TMO should note its history of innovation and strategic acquisitions, which have contributed to its robust financial performance and shareholder value creation over the past two decades.

  • 3/12/2026POSITIVE
    Here's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today

    An investment of $100 in Thermo Fisher Scientific (TMO) 15 years ago would have grown to approximately $1,040 today, representing a substantial 940% return. This performance significantly outpaced the broader market during the same period. The company's consistent growth trajectory, driven by its diversified portfolio in life sciences, diagnostics, and laboratory products, has been a key factor in its stock's appreciation. Investors who held TMO stock have benefited from its strong operational execution and strategic acquisitions, underscoring its resilience and long-term value creation potential.

  • 3/2/2026NEUTRAL
    Here's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today

    A retrospective analysis highlights the remarkable performance of Thermo Fisher Scientific, revealing how a $100 investment made two decades ago would have generated substantial returns for today's investors. While this study doesn't provide direct future guidance, it underscores the company's ability to create long-term value, driven by its leadership in life sciences, diagnostics, and research. Consistent growth and innovation have allowed Thermo Fisher to solidify its market position, transforming a modest initial capital into a significantly larger sum. For investors, this serves as a reminder of the importance of patience and selecting companies with strong fundamentals and a lasting competitive advantage.

via Markets Gazette